Clinical trial
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and…
NCT00100776 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00100776 |
|---|---|
| Title | Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder |
| Official title | Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine |
| Enrollment | 600 |
| Start date | Sep 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Jan 7, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: